ATEC Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of -30.68% compared to Alphatec Holdings's net margin of 30.99%. Alphatec Holdings's return on equity of -691.37% beat Intuitive Surgical's return on equity of 15.82%.

Alphatec Holdings has a consensus price target of $18.32, signalling upside risk potential of 53.68%. On the other hand Intuitive Surgical has an analysts' consensus of $578.17 which suggests that it could grow by 9.89%. Given that Alphatec Holdings has higher upside potential than Intuitive Surgical, analysts believe Alphatec Holdings is more attractive than Intuitive Surgical.

Alphatec Holdings has a beta of 1.104, which suggesting that the stock is 10.381% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Alphatec Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alphatec Holdings pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Alphatec Holdings quarterly revenues are $169.2M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Alphatec Holdings's net income of -$51.9M is lower than Intuitive Surgical's net income of $698.4M. Notably, Alphatec Holdings's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 77.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alphatec Holdings is 2.68x versus 21.92x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of -30.68% compared to Alphatec Holdings's net margin of -27.42%. Alphatec Holdings's return on equity of -691.37% beat Orthofix Medical's return on equity of -27.48%.

Alphatec Holdings has a consensus price target of $18.32, signalling upside risk potential of 53.68%. On the other hand Orthofix Medical has an analysts' consensus of $24.40 which suggests that it could grow by 120.82%. Given that Orthofix Medical has higher upside potential than Alphatec Holdings, analysts believe Orthofix Medical is more attractive than Alphatec Holdings.

Alphatec Holdings has a beta of 1.104, which suggesting that the stock is 10.381% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 0.801, suggesting its less volatile than the S&P 500 by 19.856%.

Alphatec Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alphatec Holdings pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

Alphatec Holdings quarterly revenues are $169.2M, which are smaller than Orthofix Medical quarterly revenues of $193.6M. Alphatec Holdings's net income of -$51.9M is higher than Orthofix Medical's net income of -$53.1M. Notably, Alphatec Holdings's price-to-earnings ratio is -- while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alphatec Holdings is 2.68x versus 0.53x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -30.68% compared to Alphatec Holdings's net margin of 6.22%. Alphatec Holdings's return on equity of -691.37% beat Insulet's return on equity of 36.9%.

Alphatec Holdings has a consensus price target of $18.32, signalling upside risk potential of 53.68%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.52%. Given that Alphatec Holdings has higher upside potential than Insulet, analysts believe Alphatec Holdings is more attractive than Insulet.

Alphatec Holdings has a beta of 1.104, which suggesting that the stock is 10.381% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Alphatec Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alphatec Holdings pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Alphatec Holdings quarterly revenues are $169.2M, which are smaller than Insulet quarterly revenues of $569M. Alphatec Holdings's net income of -$51.9M is lower than Insulet's net income of $35.4M. Notably, Alphatec Holdings's price-to-earnings ratio is -- while Insulet's PE ratio is 54.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alphatec Holdings is 2.68x versus 10.28x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of -30.68% compared to Alphatec Holdings's net margin of -55.69%. Alphatec Holdings's return on equity of -691.37% beat Tandem Diabetes Care's return on equity of -81.14%.

Alphatec Holdings has a consensus price target of $18.32, signalling upside risk potential of 53.68%. On the other hand Tandem Diabetes Care has an analysts' consensus of $35.25 which suggests that it could grow by 74.25%. Given that Tandem Diabetes Care has higher upside potential than Alphatec Holdings, analysts believe Tandem Diabetes Care is more attractive than Alphatec Holdings.

Alphatec Holdings has a beta of 1.104, which suggesting that the stock is 10.381% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.517, suggesting its more volatile than the S&P 500 by 51.705%.

Alphatec Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alphatec Holdings pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Alphatec Holdings quarterly revenues are $169.2M, which are smaller than Tandem Diabetes Care quarterly revenues of $234.4M. Alphatec Holdings's net income of -$51.9M is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, Alphatec Holdings's price-to-earnings ratio is -- while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alphatec Holdings is 2.68x versus 1.35x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.